Jarden Reaffirms Their Hold Rating on Brambles (BMBLF)
Don't Miss TipRanks' Half-Year Sale
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Cakarnis covers the Industrials sector, focusing on stocks such as Brambles , ALS, and Aurizon Holdings. According to TipRanks, Cakarnis has an average return of 10.6% and a 68.42% success rate on recommended stocks.
Currently, the analyst consensus on Brambles is a Moderate Buy with an average price target of $14.14.
Based on Brambles 's latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $3.48 billion and a net profit of $446.2 million. In comparison, last year the company earned a revenue of $3.42 billion and had a net profit of $391.3 million
Based on the recent corporate insider activity of 11 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of BMBLF in relation to earlier this year.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
4 hours ago
- Business Insider
Samsung reports Mobile Experience / Network revenue KRW 3.1T vs. KRW 2.2T y/y
In Q2 Mobile Experience, says: Smartphone shipments decreased compared to Q1 when new models released, Grew both revenue and OP YoY by robust sales of S25 series, A series and Tablets Maintained solid double-digit profitability via efficient resource management. For the second half, Samsung (SSNLF) looks to: Focus on flagship sales of foldables/S25 series and emphasize AI on A series as well as reinforce AI for tablet/wearables and launch new form-factor products such as XR/TriFold to expand ecosystem and pursue solid profitability despite uncertainties and BOM cost burden. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Business Insider
5 hours ago
- Business Insider
Morgan Stanley Keeps Their Buy Rating on Tuas Ltd. (TUA)
In a report released today, James Bales from Morgan Stanley maintained a Buy rating on Tuas Ltd., with a price target of A$7.00. The company's shares opened today at A$5.13. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. According to TipRanks, Bales is a 2-star analyst with an average return of 0.4% and a 40.96% success rate. Bales covers the Consumer Cyclical sector, focusing on stocks such as Collins Foods , Corporate Travel Management Limited, and Temple & Webster Group Ltd. In addition to Morgan Stanley, Tuas Ltd. also received a Buy from Citi's William Park CPA in a report issued on July 29. However, on July 28, TR | OpenAI – 4o initiated coverage with a Hold rating on Tuas Ltd. (ASX: TUA).
Business Insider
5 hours ago
- Business Insider
Atlas Arteria (MAQAF) Receives a Hold from Morgan Stanley
In a report released today, Robert Koh from Morgan Stanley maintained a Hold rating on Atlas Arteria, with a price target of A$5.26. The company's shares closed last Monday at $3.50. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. According to TipRanks, Koh is a 3-star analyst with an average return of 2.2% and a 52.00% success rate. Koh covers the Energy sector, focusing on stocks such as Origin Energy Limited, Ampol Limited, and Viva Energy Group Ltd.. In addition to Morgan Stanley, Atlas Arteria also received a Hold from Morgans's Nathan Lead in a report issued today. However, on the same day, Citi maintained a Buy rating on Atlas Arteria (Other OTC: MAQAF). Based on Atlas Arteria's latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $76.3 million and a net profit of $161.1 million. In comparison, last year the company earned a revenue of $70.5 million and had a net profit of $119.8 million
